Atrial fibrillation
Drug research and approvals for atrial fibrillation: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 518 studies of atrial fibrillation are recruiting on ClinicalTrials.gov, Health Canada has authorized 41 drug trials for it since 2013, FDA has 1 approved and 1 open orphan designations naming it, and the EU has 5 authorised medicines for it.
- Recruiting worldwide: 518
- Trials authorized in Canada: 41
- FDA orphan approvals: 1
- EU medicines: 5
- Prognostic Value of 2-Week ECG Monitoring After PCI in Acute Myocardial InfarctionNCT07947498 · Not applicable · Chungnam National University Hospital · starts Aug 2, 2024
- A Feasibility Study of a Wearable Arrhythmia Monitoring System (PulseON) in Stroke PatientsNCT07943065 · Not reported · University Hospitals Coventry and Warwickshire NHS Trust · starts Sep 16, 2026
- AI-Based Tools for Stroke Diagnosis, Treatment and Outcome Prediction: a Multicentre Prospective Observational StudyNCT07924371 · Not reported · Hospital Universitari Vall d'Hebron Research Institute · starts Sep 28, 2026
- Structured Treatment and Resource Efficiency Assessment With Lean Six Sigma Integration for Pulmonary Vein IsolationNCT07910370 · Not applicable · St. Josefs-Hospital Wiesbaden GmbH · starts Oct 26, 2026
- A Comparison of Pulsed Field Ablation (PFA) vs Cryoablation for Atrial Fibrillation Under Deep SedationNCT07900685 · Not applicable · East Sussex Healthcare NHS Trust · starts Oct 19, 2026
- Renal Denervation in Patients With Atrial Fibrillation and HypertensionNCT07893821 · Not applicable · Pavel Antiperovitch · starts Aug 1, 2026
- Comparison of Two Pulse Field Ablation Systems for AF AblationNCT07883629 · Not applicable · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · starts Jul 10, 2026
- Conscious Sedation Versus General Anesthesia for Pulsed Field Ablation in Paroxysmal Atrial FibrillationNCT07877519 · Not applicable · China National Center for Cardiovascular Diseases · starts Jun 1, 2026
- Bachmann's Bundle Versus Right Atrial Appendage PacingNCT07874763 · Not applicable · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · starts Aug 19, 2025
Approved 13
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- RivaroxabanCoagulation factor X inhibitor
- ApixabanCoagulation factor X inhibitor
- DronedaroneVoltage-gated L-type calcium channel blocker
- DigoxinSodium/potassium-transporting ATPase inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- PropafenoneBeta-1 adrenergic receptor antagonist
- VernakalantKir3.1/Kir3.4 blocker
- EdoxabanCoagulation factor X inhibitor
- DofetilideHERG blocker
- DiltiazemVoltage-gated L-type calcium channel blocker
- Dabigatran etexilateThrombin inhibitor
- LandiololBeta-1 adrenergic receptor antagonist
Phase 3 12 of 54
- AmiodaroneHERG blocker
- ColchicineTubulin inhibitor
- SotalolBeta-1 adrenergic receptor antagonist
- SpironolactoneMineralocorticoid receptor antagonist
- AspirinCyclooxygenase inhibitor
- FlecainideSodium channel protein type V alpha subunit blocker
- DabigatranThrombin inhibitor
- MetoprololBeta-1 adrenergic receptor antagonist
- RanolazineSodium channel protein type V alpha subunit blocker
- Ascorbic acidSupplement
- Vitamin k
- IrbesartanType-1 angiotensin II receptor antagonist
Phase 2 12 of 35
- OnabotulinumtoxinaSynaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
- AZD1305HERG blocker
- Atecegatran metoxilThrombin inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- BetrixabanCoagulation factor X inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- Celivarone
- DarexabanCoagulation factor X inhibitor
- BMS-919373
- Sulcardine
- RimabotulinumtoxinbVesicle-associated membrane protein 2 inhibitor
- BupivacaineSodium channel protein type IV alpha subunit blocker
Phase 1 or earlier 4
- LiothyronineThyroid hormone receptor agonist
- OdiparcilGlycosaminoglycans modulator
- Gemibotulinumtoxin a
- Calcium carbonate
How its trials ended
3,474 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 720 whose ending is known, 46% met their primary endpoint, 8% missed it and 45% stopped early.
- Completed, result not reported1,29437%
- Ongoing84124%
- Status unknown61918%
- Met its primary endpoint33310%
- Stopped: other or unclear1615%
- Stopped: enrollment or feasibility1033%
- Missed its primary endpoint602%
- Stopped: sponsor or business decision351%
- Stopped: lack of efficacy16<1%
- Stopped: funding8<1%
- Stopped: safety4<1%
| Jul 2, 2026 | A master protocol for a phase 3, randomized, multicenter, double-blind study to assess stroke and systemic embolism prevention with REGN7508 and REGN9933,…REGN7508 / REGN9933 | Regeneron | Ongoing |
| Sep 11, 2025 | A phase 2, randomized, multicenter, open-label, blinded-endpoint study to evaluate the safety of REGN7508 and REGN9933, monoclonal antibodies against fxi,…REGN7508 / REGN9933 | Regeneron | Ongoing |
| Jul 3, 2025 | A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as…PKN605 | Novartis Pharmaceuticals | Ongoing |
| Mar 5, 2025 | Multi-center, placebo-controlled, phase 3 study of etripamil nasal spray (NS) in patients with atrial fibrillation and rapid ventricular rate (RVR)Etripamil (MSP-2017) | Milestone Pharmaceuticals | Ongoing |
| Jul 26, 2023 | Start-poaf -short term anti-arrhythmic therapy for post-operative af in cardiac surgery patients (start-poaf) pilot trialAmiodarone | Hamilton Health Sciences Corporation | Ongoing |
| May 10, 2023 | A phase 3, randomized, double-blind, double-dummy, parallel group, active-controlled study to evaluate the efficacy and safety of milvexian, an oral factor xia…Milvexian (JNJ-70033093; BMS-986177) / Apixaban | Johnson & Johnson | Ongoing |
| Apr 20, 2023 | Use of magnesium prophylaxis for the prevention of atrial fibrillation in critically ill patients : atomic pilot studyMagnesium | Kingston Health Science Centre | Ongoing |
| Jan 19, 2023 | A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of abelacimab in high-risk…Abelacimab (MAA868) | Anthos Therapeutics, Inc. | Ongoing |
| Nov 3, 2022 | A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, phase 3 study to compare the…Asundexian (bay 2433334) | Bayer | Closed |
| Jun 1, 2022 | A phase 3, randomized, double-blind, placebo-controlled trial of flecainide acetate inhalation solution for cardioversion of recent-onset, symptomatic atrial…Flecainide (FLECIH-103) | InCarda Therapeutics | Closed |
| Jul 2, 2009 | So-AqueousFor use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of… | AltaThera Pharmaceuticals LLC | Approved |
| Mar 7, 2019 | TecarfarinPrevention of systemic thromboembolism of cardiac origin in patients with End Stage Renal Disease and atrial fibrillation | Cadrenal Therapeutics, Inc. | Designated |
| Jul 23, 2020 | Apixaban AccordApixaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Apr 19, 2017 | RoteasEdoxaban | Berlin-Chemie AG | EMA ↗ |
| Jun 19, 2015 | LixianaEdoxaban | Daiichi Sankyo Europe GmbH | EMA ↗ |
| Sep 1, 2010 | BrinavessVernakalant hydrochloride | Advanz Pharma Limited | EMA ↗ |
| Nov 25, 2009 | MultaqDronedarone | Sanofi Winthrop Industrie | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA